Selective to tumors, safe for patients.

We aim at a high selectivity in the treatment for solid tumors, boosting efficacy while reducing adverse effects.

We aim at improving patients’ Quality of Life.">
Seekyo Therapeutics
Edit

Seekyo Therapeutics

https://www.seekyo-therapeutics.com/
Last activity: 26.10.2020
Active
Categories: BioTechDeliveryDrugLifePlatformScienceSmartTechnology
Seekyo is a biotechnology company developing a Tumor Micro Environment Targeting "Smart Chemotherapy" :
Selective to tumors, safe for patients.

We aim at a high selectivity in the treatment for solid tumors, boosting efficacy while reducing adverse effects.

We aim at improving patients’ Quality of Life.
Followers
625
Mentions
4
Location: France, New Aquitaine, Chasseneuil-du-Poitou
Employees: 1-10
Total raised: $887.72K
Founded date: 2018

Investors 1

DateNameWebsite
03.03.2021Business A...business-a...

Funding Rounds 1

DateSeriesAmountInvestors
20.01.2020Seed$887.72K-

Mentions in press and media 4

DateTitleDescription
26.10.202021 start-ups reach EIT Health Catapult FinalTwenty-one start-ups from across Europe have secured their places at the EIT Health Catapult Final in December. The EIT Health Catapult, currently in its fifth year, is a training and competition programme that boosts the development of Eu...
13.06.202042 start-ups reach EIT Health Catapult Semi-finalsThe EIT Health Catapult, currently in its fifth year of operation, is a training and competition programme that boosts the development of European health start-ups by exposing them to top quality experts and international investors. The 42...
20.01.2020Seekyo Raises €800k in Seed FundingSeekyo, a Poitiers, France-based biotech startup specializing in the development of the next generation of chemotherapies, raised €800k in funding. Backers included the French Tech Seed Fund and investors from the BAdGE, INVESTESSOR and SYN...
20.01.2020French biotech Seekyo raises €800,000 to test its tumor-targeting smart chemotherapySeekyo, a Poitiers-based biotech startup developing new chemotherapies, has raised €800,000 in seed funding to validate its flagship tumor-targeting drug. The financing consists of €400,000 from angel investors in the BAdGE, Investessor, an...

Reviews 0

Sign up to leave a review

Sign up Log In